
Travere Therapeutics (TVTX) Stock Forecast & Price Target
Travere Therapeutics (TVTX) Analyst Ratings
Bulls say
Travere Therapeutics is viewed positively because FILSPARI is demonstrating strong commercial momentum, with 2Q26 revenue of $141.1M and 2,012 new patient start forms, while physician surveys point to rising use in both IgAN and FSGS. The newly allowed USPTO patent for FSGS methods, expected to extend coverage into October 2037 and match the IgAN patent, materially reduces exclusivity risk around the franchise’s main growth driver. In addition, the planned CEO transition to Bradley Campbell and the continued advancement of pegtibatinase and civorebrutinib give the company a credible path to diversify beyond FILSPARI while preserving execution strength.
Bears say
Travere Therapeutics is facing a fundamentally fragile outlook despite its $489.2M cash, cash equivalents and marketable securities at the end of 1Q 2026, because that balance may only support operations into the future and does not eliminate financing risk. The company may need to access the capital markets to fund its portfolio and commercialization efforts, and any follow-on stock offering could dilute current shareholders if additional capital is raised. Beyond financing, delays or setbacks in commercializing Filspari or pegtibatinase could materially reduce sales potential, while constrained capital market access would limit its ability to advance development or bring products to market.
This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Travere Therapeutics (TVTX) Analyst Forecast & Price Prediction
Start investing in Travere Therapeutics (TVTX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Travere Therapeutics (TVTX) Forecast
Travere Therapeutics (TVTX) Analyst Forecast & Price Prediction
Start investing in Travere Therapeutics (TVTX)
Order type
Buy in
Order amount
Est. shares
0 shares